FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1963664515> ?p ?o ?g. }

• W1963664515 endingPage "46" @default.
• W1963664515 startingPage "41" @default.
• W1963664515 abstract "Objective Test the safety and efficacy of sequentially blocking angiogenesis by adding oral cyclophosphamide to bevacizumab following cancer progression on bevacizumab in patients with recurrent ovarian cancer. Methods Eligibility included ≤2 lines of treatment for recurrence and measurable cancer by RECIST 1.0. Patients received bevacizumab (15 mg/kg every 3 weeks IV) and upon RECIST progression, oral cyclophosphamide (50 mg orally daily) was added. Objectives included safety, toxicities, 3- and 6-month PFS rates, response rate, PFS, and OS. Results 20 patients were enrolled. Overall response rate was 10%, and 65% of patients had confirmed stable disease (SD). Thirteen of 20 patients received oral cyclophosphamide added to bevacizumab upon bevacizumab progression. Of these 13 patients, 1 patient subsequently achieved a PR (this patient had SD as best response during bevacizumab) and 3 patients had a confirmed SD. For all patients, median PFS was 8.41 months, 6 month PFS rate was 65%, duration of response (DOR) was 7.3 months, and median OS was 22.72 months. Median DOR for patients receiving both bevacizumab and cyclophosphamide was 8.4 months. Most toxicities were grades 1 and 2 and manageable. Grades 3 and grade 4 toxicities included 1 myocardial infarction, 1 gastrointestinal perforation (GIP), and 12/20 patients (60%) developed grade 3 HTN. Conclusions Addition of oral cyclophosphamide to bevacizumab at the time of cancer progression on bevacizumab appears to have continued anti-cancer effects in a subgroup of patients and appears to be safe. Randomized trials testing combination versus sequential anti-angiogenic therapy for recurrent ovarian cancer are warranted." @default.
• W1963664515 created "2016-06-24" @default.
• W1963664515 creator A5008083559 @default.
• W1963664515 creator A5035610387 @default.
• W1963664515 creator A5037937774 @default.
• W1963664515 creator A5047011419 @default.
• W1963664515 creator A5058249824 @default.
• W1963664515 creator A5060953135 @default.
• W1963664515 creator A5074596928 @default.
• W1963664515 creator A5075304343 @default.
• W1963664515 creator A5090981731 @default.
• W1963664515 creator A5091757228 @default.
• W1963664515 date "2012-07-01" @default.
• W1963664515 modified "2023-10-14" @default.
• W1963664515 title "Sequential bevacizumab and oral cyclophosphamide for recurrent ovarian cancer" @default.
• W1963664515 cites W1913802169 @default.
• W1963664515 cites W1960327677 @default.
• W1963664515 cites W1994855668 @default.
• W1963664515 cites W2010066843 @default.
• W1963664515 cites W2018929154 @default.
• W1963664515 cites W2029883816 @default.
• W1963664515 cites W2041555738 @default.
• W1963664515 cites W2049792735 @default.
• W1963664515 cites W2059294866 @default.
• W1963664515 cites W2068796910 @default.
• W1963664515 cites W2096521047 @default.
• W1963664515 cites W2101711321 @default.
• W1963664515 cites W2105651363 @default.
• W1963664515 cites W2109400578 @default.
• W1963664515 cites W2113122060 @default.
• W1963664515 cites W2117923595 @default.
• W1963664515 cites W2126333580 @default.
• W1963664515 cites W2128011232 @default.
• W1963664515 cites W2128178813 @default.
• W1963664515 cites W2132193955 @default.
• W1963664515 cites W2135947389 @default.
• W1963664515 cites W2137268781 @default.
• W1963664515 cites W2139248078 @default.
• W1963664515 cites W2140640502 @default.
• W1963664515 cites W2141652044 @default.
• W1963664515 cites W2154056804 @default.
• W1963664515 cites W2154885792 @default.
• W1963664515 cites W2169965478 @default.
• W1963664515 cites W2328421677 @default.
• W1963664515 cites W4249741185 @default.
• W1963664515 doi "https://doi.org/10.1016/j.ygyno.2012.04.003" @default.
• W1963664515 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22487536" @default.
• W1963664515 hasPublicationYear "2012" @default.
• W1963664515 type Work @default.
• W1963664515 sameAs 1963664515 @default.
• W1963664515 citedByCount "15" @default.
• W1963664515 countsByYear W19636645152013 @default.
• W1963664515 countsByYear W19636645152014 @default.
• W1963664515 countsByYear W19636645152015 @default.
• W1963664515 countsByYear W19636645152016 @default.
• W1963664515 countsByYear W19636645152020 @default.
• W1963664515 countsByYear W19636645152023 @default.
• W1963664515 crossrefType "journal-article" @default.
• W1963664515 hasAuthorship W1963664515A5008083559 @default.
• W1963664515 hasAuthorship W1963664515A5035610387 @default.
• W1963664515 hasAuthorship W1963664515A5037937774 @default.
• W1963664515 hasAuthorship W1963664515A5047011419 @default.
• W1963664515 hasAuthorship W1963664515A5058249824 @default.
• W1963664515 hasAuthorship W1963664515A5060953135 @default.
• W1963664515 hasAuthorship W1963664515A5074596928 @default.
• W1963664515 hasAuthorship W1963664515A5075304343 @default.
• W1963664515 hasAuthorship W1963664515A5090981731 @default.
• W1963664515 hasAuthorship W1963664515A5091757228 @default.
• W1963664515 hasConcept C121608353 @default.
• W1963664515 hasConcept C126322002 @default.
• W1963664515 hasConcept C141071460 @default.
• W1963664515 hasConcept C143998085 @default.
• W1963664515 hasConcept C2776694085 @default.
• W1963664515 hasConcept C2776755627 @default.
• W1963664515 hasConcept C2777802072 @default.
• W1963664515 hasConcept C2778822529 @default.
• W1963664515 hasConcept C2779984678 @default.
• W1963664515 hasConcept C2780427987 @default.
• W1963664515 hasConcept C71924100 @default.
• W1963664515 hasConcept C90924648 @default.
• W1963664515 hasConceptScore W1963664515C121608353 @default.
• W1963664515 hasConceptScore W1963664515C126322002 @default.
• W1963664515 hasConceptScore W1963664515C141071460 @default.
• W1963664515 hasConceptScore W1963664515C143998085 @default.
• W1963664515 hasConceptScore W1963664515C2776694085 @default.
• W1963664515 hasConceptScore W1963664515C2776755627 @default.
• W1963664515 hasConceptScore W1963664515C2777802072 @default.
• W1963664515 hasConceptScore W1963664515C2778822529 @default.
• W1963664515 hasConceptScore W1963664515C2779984678 @default.
• W1963664515 hasConceptScore W1963664515C2780427987 @default.
• W1963664515 hasConceptScore W1963664515C71924100 @default.
• W1963664515 hasConceptScore W1963664515C90924648 @default.
• W1963664515 hasIssue "1" @default.
• W1963664515 hasLocation W19636645151 @default.
• W1963664515 hasLocation W19636645152 @default.
• W1963664515 hasOpenAccess W1963664515 @default.
• W1963664515 hasPrimaryLocation W19636645151 @default.
• W1963664515 hasRelatedWork W1968540912 @default.

• next